Alcon to buy Aerie Pharmaceuticals in $753 mln deal
In This Article:
Aug 23 (Reuters) - Swiss eye-care device maker Alcon AG said on Tuesday it would acquire Aerie Pharmaceuticals for $15.25 per share, valuing it at about $753 million.
Alcon said the deal is expected to be accretive to company's core diluted earnings per share in 2024. (Reporting by Rachna Dhanrajani in Bengaluru; Editing by Rashmi Aich)
Terms and Privacy Policy